<p>We examined genetic resistance to second generation androgen targeting therapies (abiraterone acetate or enzalutamide) by analyzing whole exome sequencing of patient-matched pre-treatment and post-resistance tumors from a series of castrate-resistant prostate cancer (CRPC) patients. Abiraterone resistant tumors harbored alterations in AR and MYC, whereas patients treated with enzalutamide had acquired alterations in the cell cycle pathway. We experimentally confirmed expression of cell-cycle kinases sufficed to drive enzalutamide resistance, which was mitigated through CDK4/6 blockade. These observations link genetic resistance to specific therapeutic agents to inform strategies in genomically selected advanced CRPC.</p>

Metastatic Castrate-Resistant Prostate Cancer Study (MCRPCS)

Prostatic Neoplasms study with WXS data on dbGaP (7 participants)

Metastatic Castrate-Resistant Prostate Cancer Study (MCRPCS)

Description

Applying For Access

Summary